Terms: = Kidney tumors AND RHOH, TTF, 399, ENSG00000168421, ARHH, RhoH AND Clinical Outcome
3 results:
1. clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators.
Stellato M; Procopio G; De Giorgi U; Maruzzo M; Bimbatti D; Mennitto A; Sbrana A; Roviello G; Casadei C; Sepe P; Pignata S; Santini D
J Transl Med; 2021 Aug; 19(1):328. PubMed ID: 34344414
[TBL] [Abstract] [Full Text] [Related]
2. 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.
Krajewski KM; Franchetti Y; Nishino M; Fay AP; Ramaiya N; Van den Abbeele AD; Choueiri TK
Oncologist; 2014 May; 19(5):507-14. PubMed ID: 24755461
[TBL] [Abstract] [Full Text] [Related]
3. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
[TBL] [Abstract] [Full Text] [Related]
